文献速递肝病消化道肿瘤与早癌

射频消融作为肝细胞癌肝移植桥接治疗:10年意向性治疗分析

Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10-year intention-to-treat analysis.
PubMed 文献 · Hepatology · 2017-04-28

本研究对2004年3月至2014年10月间121例等待肝移植的肝细胞癌患者(156个新发肿瘤,平均大小2.4 cm)行射频消融作为初始单独桥接治疗,随访中位42.9个月,评估等待名单脱落率、移植后复发及10年意向性治疗生存。因肿瘤进展脱落者占7.4%,移植后复发占5.6%,意向性治疗10年总生存率41.2%、无复发生存率37.7%、疾病特异性生存率89.5%。结论认为射频消融作为一线单独桥接治疗可获得良好的长期总体及肿瘤特异性生存,脱落率低且移植后复发率持续较低。

要点

  • 因肿瘤进展从等待名单脱落者占7.4%。
  • 肝移植后肝细胞癌复发者占5.6%。
  • 意向性治疗10年总生存率41.2%,疾病特异性生存率89.5%。

核心结论

  • 射频消融作为肝移植前一线单独桥接治疗可获得良好的长期总体生存和肿瘤特异性生存,尽管等待名单时间长,因肿瘤进展的脱落率低,移植后随访至10年肿瘤复发率持续较低。

研究设计与样本

  • 长期(10年)研究,2004年3月至2014年10月对121例等待原位肝移植的肝细胞癌患者(男/女比83:38,平均年龄60.0岁)行射频消融作为初始单独桥接治疗,共156个新发肝细胞癌(平均大小2.4 cm)。
  • 自首次射频消融起随访时间1.3至128.0个月(中位42.9个月)。

主要发现

  • 因肿瘤进展从等待名单脱落者占7.4%。
  • 肝移植后肝细胞癌复发者占5.6%。
  • 肝移植后5年和10年总生存率分别为75.8%和42.2%,无复发生存率分别为71.1%和39.6%。
  • 整个研究人群意向性治疗5年和10年总生存率分别为63.5%和41.2%,无复发生存率分别为60.8%和37.7%,疾病特异性生存率分别为89.5%和89.5%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: In a long-term (10-year) study of radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC) as bridging therapy in patients listed for orthotopic liver transplantation (LT), we evaluated the impact of RFA on waiting list dropout rate, post-LT tumor recurrence, and long-term intention-to-treat, disease-specific survival (DSS). From March 2004 to October 2014, RFA was performed as the initial stand-alone bridge therapy to LT for 121 patients (men/women ratio, 83:38; mean age, 60.0 years) with 156 de novo HCCs (mean size, 2.4 cm). Follow-up period from initial RFA ranged from 1.3 to 128.0 months (median, 42.9 months). We assessed the overall and tumor-specific waiting list dropout rates, post-LT tumor recurrence, and 10-year post-LT and intention-to-treat survival rates. Dropout from the waiting list due to tumor progression occurred in 7.4% of patients. HCC recurrence after LT occurred in 5.6% of patients. The post-LT overall survival (OS) rate at 5 and 10 years was 75.8% and 42.2%, respectively, and the recurrence-free survival (RFS) rate was 71.1% and 39.6%, respectively. Intention-to-treat OS, RFS, and DSS rates for the entire study population at 5 and 10 years were 63.5% and 41.2%, 60.8% and 37.7%, and 89.5% and 89.5%, respectively. CONCLUSION: RFA as a first-line stand-alone bridge therapy to LT achieves excellent long-term overall and tumor-specific survivals, with a low dropout rate from tumor progression despite long wait list times and a sustained low tumor recurrence rate upon post-LT follow-up of up to 10 years. (Hepatology 2017;65:1979-1990).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Lee MW, Raman SS, Asvadi NH, et al. Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10-year intention-to-treat analysis. Hepatology. 2017. PMID: 28170115. doi:10.1002/hep.29098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。